Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 657 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Post-Infectious Disorder (Disorder) Clear all
Completed No phase listed Observational Results available

A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

NCT00210639
View directory record Official record
Conditions
Musculoskeletal Diseases
Interventions
No intervention
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
6 Months to 16 Years
Enrollment
2,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
47
States / cities
Hoover, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

NCT02108522
View directory record Official record
Conditions
Infection
Interventions
Multivirus Specific T cells
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Early Phase 1 Interventional

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

NCT03421613
View directory record Official record
Conditions
Treatment of PHN
Interventions
3VM1001, Placebo
Drug · Other
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation

NCT05880108
View directory record Official record
Conditions
Post-COVID Conditions, Obesity
Interventions
12-weeks of Weight Loss, 12-weeks of Weight Stability
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of 935U83 in HIV-Infected Patients

NCT00002338
View directory record Official record
Conditions
HIV Infections
Interventions
Raluridine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy

NCT00177112
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
clean patient preparation for cystoscopy, sterile patient preparation for cystoscopy
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2008 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

NCT01793584
View directory record Official record
Conditions
Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
Interventions
Laparoscopic hysterectomy, Abdominal hysterectomy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

HIV Non-Occupational Post-Exposure Prophylaxis

NCT01855867
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Drug
Lead sponsor
Kenneth H. Mayer, MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Anktiva in Patients With Long Covid-19.

NCT07108036
View directory record Official record
Conditions
Long COVID
Interventions
N-803 (IL-15 Superagonist)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Immune Response to Hepatitis C Virus

NCT00006301
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Silver Spring, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 23, 2026, 9:22 AM EDT
Terminated No phase listed Observational

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

NCT05876377
View directory record Official record
Conditions
SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Interventions
Pfizer-BioNTech COVID-19 mRNA vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Enrolling by invitation No phase listed Observational

Microbial and Cytokine Signatures in Long COVID Patients

NCT07074158
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Not listed
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 23, 2026, 9:22 AM EDT
Active, not recruiting Not applicable Interventional

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

NCT06391489
View directory record Official record
Conditions
Post Acute COVID 19 Syndrome, Memory Impairment, Memory Dysfunction, Cognitive Dysfunction
Interventions
HOBSCOTCH-PACS
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Recruiting Phase 3 Interventional

Shingrix in Renal Transplant Recipients

NCT04128189
View directory record Official record
Conditions
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
Interventions
Shingrix
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

NCT04308668
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

NCT03472963
View directory record Official record
Conditions
HIV Infections
Interventions
Single dose of Genvoya® and a single 800 mg dose of Darunavir®
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 23, 2026, 9:22 AM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

VNS for Long-COVID-19

NCT05630040
View directory record Official record
Conditions
Post-COVID-19 Syndrome, Postural Tachycardia Syndrome, Dysautonomia
Interventions
Non-invasive vagus nerve stimulation, Sham Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Brain-Training Treatment for Long COVID in Older Adults

NCT05705193
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
NeuroFlex (computerized gamified tasks)
Other
Lead sponsor
UConn Health
Other
Eligibility
60 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

NCT05965752
View directory record Official record
Conditions
Long COVID, Long COVID-19, Long COVID19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 23, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Letermovir for CMV Prevention After Lung Transplantation

NCT05041426
View directory record Official record
Conditions
Lung Transplant, CMV
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 9:22 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 23, 2026, 9:22 AM EDT